

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2022 ANNUAL REPORT

Reference is made to the annual report of RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司) published on April 27, 2023 (the “**2022 Annual Report**”). Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the 2022 Annual Report. This announcement provides supplemental information to the Annual Report and should be read in conjunction with the 2022 Annual Report.

In relation to the particulars of the Awards granted pursuant to the H Share Scheme (on page 56 of the 2022 Annual Report) and the particulars of the Awards granted pursuant to the A Share Scheme (on page 58 of the 2022 Annual Report), the Company would like to provide the following supplemental information (revisions are shown in underline):

Particulars of the Awards granted pursuant to the H Share Scheme

Name of grantee	Category of grantee	Date of grant	Vesting period	Exercise period	As at January 1, 2022	Granted during the Reporting Period	Vested during the Reporting Period	Lapsed during the Reporting Period	Cancelled during the Reporting Period	As at December 31, 2022	Purchase price (HKD)	Closing price of the Shares immediately before the date when the awards were granted (HKD)	Weighted average closing price of the Shares immediately before the date when the awards were vested (HKD)
Directors													
Fang Jianmin	Executive Director and chief executive officer	September 1, 2022	September 1, 2022 to December 31, 2023	8 years	Nil	1,500,000	Nil	<u>Nil</u>	<u>Nil</u>	1,500,000	27.06	45.30	57.90
He Ruyi	Executive Director	September 1, 2022	September 1, 2022 to December 31, 2025	8 years	Nil	1,600,000	Nil	<u>Nil</u>	<u>Nil</u>	1,600,000	16.91	45.30	57.90
Five highest paid individuals during the Reporting Period⁽¹⁾													
—	Five highest paid individuals	March 22, 2022	March 22, 2022 to June 30, 2024	8 years	Nil	200,000	100,000	<u>100,000</u>	<u>Nil</u>	Nil	19.68	50.50	51.70 or 41.50
		June 30, 2022	June 30, 2022 to December 31, 2025	8 years	Nil	150,000	Nil	<u>112,500</u>	<u>Nil</u>	37,500	27.06	43.95	57.90
		March 22, 2022	March 22, 2022 to March 31, 2025	8 years	Nil	150,000	37,500	<u>Nil</u>	<u>Nil</u>	112,500	27.32	50.50	50.55
Sub-total		-	-	-	0	500,000	137,500	212,500	<u>Nil</u>	150,000	-	-	-
Others													
Other grantees	Employees	March 22, 2022	March 22, 2022 to March 31, 2025	8 years	Nil	225,000	56,250	<u>101,250</u>	<u>Nil</u>	67,500	50.50	50.50	50.55
		March 22, 2022	March 22, 2022 to June 30, 2025	8 years	Nil	115,000	23,750	<u>27,500</u>	<u>Nil</u>	63,750	50.50	50.50	41.50
		March 22, 2022	March 22, 2022 to September 30, 2025	8 years	Nil	40,000	10,000	<u>Nil</u>	<u>Nil</u>	30,000	50.50	50.50	38.10
		March 22, 2022	March 22, 2022 to December 31, 2025	8 years	Nil	20,000	Nil	<u>Nil</u>	<u>Nil</u>	20,000	50.50	50.50	57.90
		March 22, 2022	March 22, 2022 to December 31, 2025	8 years	Nil	20,000	5,000	<u>15,000</u>	<u>Nil</u>	Nil	50.50	50.50	51.70
		March 22, 2022	March 22, 2022 to June 30, 2025	8 years	Nil	150,000	37,500	<u>Nil</u>	<u>Nil</u>	112,500	52.10	50.50	41.50
		March 22, 2022	March 22, 2022 to September 30, 2024	8 years	Nil	120,000	60,000	<u>Nil</u>	<u>Nil</u>	60,000	26.37	50.50	51.70
		March 22, 2022	March 22, 2022 to December 31, 2024	8 years	Nil	5,000	1,250	<u>Nil</u>	<u>Nil</u>	3,750	27.00	50.50	51.70
		March 22, 2022	March 22, 2022 to December 31, 2024	8 years	Nil	15,000	3,750	<u>Nil</u>	<u>Nil</u>	11,250	27.06	50.50	51.70
		March 31, 2022	March 31, 2022 to March 31, 2026	8 years	Nil	395,000	Nil	<u>25,000</u>	<u>Nil</u>	370,000	48.37	46.50	50.55
		June 30, 2022	June 30, 2022 to December 31, 2025	8 years	Nil	84,000	Nil	<u>Nil</u>	<u>Nil</u>	84,000	27.06	43.95	57.90
		September 1, 2022	September 1, 2022 to December 31, 2025	8 years	Nil	68,000	Nil	<u>Nil</u>	<u>Nil</u>	68,000	27.06	45.30	57.90
		September 30, 2022	September 30, 2022 to September 30, 2026	8 years	Nil	60,000	Nil	<u>60,000</u>	<u>Nil</u>	Nil	38.42	38.05	38.10
		September 30, 2022	September 30, 2022 to September 30, 2026	8 years	Nil	7,156	Nil	<u>Nil</u>	<u>Nil</u>	7,156	Nil	38.05	38.10
		December 31, 2022	December 31, 2022 to December 31, 2026	8 years	Nil	400,000	Nil	<u>Nil</u>	<u>Nil</u>	400,000	39.26	57.90	57.90
		December 31, 2022	December 31, 2022 to December 31, 2026	8 years	Nil	64,224	Nil	<u>Nil</u>	<u>Nil</u>	64,224	Nil	57.90	57.90
Sub-total		-	-	-	Nil	1,788,380	197,500	228,750	<u>Nil</u>	1,362,130	-	-	-

Notes:

(1) The five highest paid individuals exclude one executive Director and the chief executive as disclosed above.

Particulars of the Awards granted pursuant to the A Share Scheme

Name of grantee	Category of grantee	Date of grant	Vesting period	Exercise period	As at 1 January 2022	Granted during the Reporting Period	Vested during the Reporting Period	Lapsed during the Reporting Period	Cancelled during the Reporting Period	As at 31 December 2022	Grant price (RMB)	Closing price of the Shares immediately before the date when the awards were granted (RMB)	Weighted average closing price of Shares immediately before the date when the awards were vested
<i>Directors, chief executive, substantial shareholders and their respective associates</i>													
Wang Weidong	Executive Director	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	350,000	Nil	Nil	Nil	350,000	36.36	75.05	N/A
He Ruyi	Executive Director	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	24,200	Nil	Nil	Nil	24,200	36.36	75.05	N/A
Lin Jian	Executive Director	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	14,850	Nil	Nil	Nil	14,850	36.36	75.05	N/A
Wen Qingkai	Substantial shareholder, Board secretary	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	18,150	Nil	Nil	Nil	18,150	36.36	75.05	N/A
Yang Minhua	Substantial shareholder	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	14,850	Nil	Nil	Nil	14,850	36.36	75.05	N/A
Wei Jianliang	Substantial shareholder	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	14,850	Nil	Nil	Nil	14,850	36.36	75.05	N/A
Jiang Jing	Spouse of Wang Liqiang	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	18,150	Nil	Nil	Nil	18,150	36.36	75.05	N/A
Wang Yuxiao	Son of Mr. Wang Weidong	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	11,000	Nil	Nil	Nil	11,000	36.36	75.05	N/A
Wang Yinxiao	Son of Wang Xudong	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	10,000	Nil	Nil	Nil	10,000	36.36	75.05	N/A
Yao Xuejing	Spouse of Supervisor Li Zhuanglin	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	33,000	Nil	Nil	Nil	33,000	36.36	75.05	N/A
<i>Others</i>													
Other grantees	Employees	December 28, 2022	December 28, 2022 to December 27, 2028	N/A	Nil	2,360,400	Nil	14,850	Nil	2,345,550	36.36	75.05	N/A

The information contained in this announcement does not affect the other information contained in the 2022 Annual Report. Save as disclosed in this announcement, all the other information and contents in the 2022 Annual Report remain unchanged.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, PRC
September 11, 2023

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive directors.

* For identification purpose only